The effect of tacrolimus (FK-506) on Japanese patients with refractory Crohn's disease

Journal of Gastroenterology

Volumn 43, Issue 10, 2008, Pages 774-779

  Tamaki, Hiroyuki ^a   Nakase, Hiroshi ^a   Matsuura, Minoru ^a   Inoue, Satoko ^a   Mikami, Sakae ^a   Ueno, Satoru ^a   Uza, Norimitsu ^a   Kitamura, Hiroshi ^a   Kasahara, Katsuhiro ^a   Chiba, Tsutomu ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Crohn's disease; FK 506; Immunosuppressant; Inflammatory bowel disease; Tacrolimus; Trough level

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; INFLIXIMAB; MESALAZINE; PREDNISOLONE; STEROID; TACROLIMUS;

ADULT; ANUS FISTULA; ARTICLE; BURNING SENSATION; CLINICAL ARTICLE; COLON FISTULA; CONTINUOUS INFUSION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROHN DISEASE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FACE DISORDER; FACE SUFFUSION; FEMALE; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; ILEAL STENOSIS; INTESTINE STENOSIS; JAPANESE; MAINTENANCE THERAPY; MALE; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PARESTHESIA; PERIANAL ABSCESS; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PSOAS ABSCESS; REFRACTORY CROHN DISEASE; RELAPSE; REMISSION; SIDE EFFECT; SIGMOIDAL STENOSIS; STENOSIS; THERAPY EFFECT; TREATMENT DURATION; TREMOR;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; COHORT STUDIES; CROHN DISEASE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JAPAN; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; TACROLIMUS; TREATMENT OUTCOME;

EID: 55349125318     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-008-2229-y     Document Type: Article

References (28)

1. Kino T, Inamura N, Sakai F, Nakahara K, Goto T, Okuhara M, et al. Effect of FK-506 on human mixed lymphocyte reaction in vitro. Transplant Proc 1987;19:36-39.
2. Kino T, Hatanaka H, Miyata S, Inamura N, Nishiyama M, Yajima T, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo) 1987;40:1256-1265.
3. Goto T, Kino T, Hatanaka H, Nishiyama M, Okuhara M, Kohsaka M, et al. Discovery of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. Transplant Proc 1987;19:4-8.
4. Busuttil RW, Lake JR. Role of tacrolimus in the evolution of liver transplantation. Transplantation 2004;77:S44-S51.
5. Vincenti F. A decade of progress in kidney transplantation. Transplantation 2004;77:S52-S61.
6. Goulet O, Michel JL, Jobert A, Damotte D, Colomb V, Cezard JP, et al. Small bowel transplantation alone or with the liver in children: Changes by using FK506. Transplant Proc 1998;30:1569-1570.
7. Zabawski EJ, Costner M, Cohen JB, Cockerell CJ. Tacrolimus: Pharmacology and therapeutic uses in dermatology. Int J Dermatol 2000;39:721-727.
8. Ierardi E, Principi M, Francavilla R, Pisani A, Rendina M, Ingrosso M, et al. Oral tacrolimus long-term therapy in patients with Crohn's disease and steroid resistance. Aliment Pharmacol Ther 2001;15:371-377.
9. Hogenauer C, Wenzl HH, Hinterleitner TA, Petritsch W. Effect of oral tacrolimus (FK 506) on steroid-refractory moderate/severe ulcerative colitis. Aliment Pharmacol Ther 2003;18:415-423.
10. Sandborn WJ, Present DH, Isaacs KL, Wolf DC, Greenberg E, Hanauer SB, et al. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: A randomized, placebo-controlled trial. Gastroenterology 2003;125:380-388.
11. Gonzalez-Lama Y, Abreu L, Vera MI, Pastrana M, Tabernero S, Revilla J, et al. Long-term oral tacrolimus therapy in refractory to infliximab fistulizing Crohn's disease: A pilot study. Inflamm Bowel Dis 2005;11:8-15.
12. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980;1:514.
13. Befeler AS, Lissoos TW, Schiano TD, Conjeevaram H, Dasgupta KA, Millis JM, et al. Clinical course and management of inflammatory bowel disease after liver transplantation. Transplantation 1998;65:393-396.
14. Fellermann K, Ludwig D, Stahl M, David-Walek T, Stange EF. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). Am J Gastroenterol 1998;93:1860-1866.
15. Egan LJ, Sandborn WJ, Tremaine WJ. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine. Am J Gastroenterol 1998;93:442-448.
16. Matsuhashi N, Nakajima A, Watanabe K, Komeno Y, Suzuki A, Ohnishi S, et al. Tacrolimus in corticosteroid-resistant ulcerative colitis. J Gastroenterol 2000;35:635-640.
17. Ogata H, Matsui T, Nakamura M, Iida M, Takazoe M, Suzuki Y, Hibi T. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006;55:1255-1262.
18. Hanke JH, Nichols LN, Coon ME. FK506 and rapamycin selectively enhance degradation of IL-2 and GM-CSF mRNA. Lymphokine Cytokine Res 1992;11:221-231.
19. Wang SC, Jordan ML, Tweardy DJ, Wright J, Hoffman RA, Simmons RL. FK-506 inhibits proliferation and IL-4 messenger RNA production by a T-helper 2 cell line. J Surg Res 1992;53:199-202.
20. Tocci MJ, Matkovich DA, Collier KA, Kwok P, Dumont F, Lin S, et al. The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J Immunol 1989;143:718-726.
21. Gummert JF, Ikonen T, Morris RE. Newer immunosuppressive drugs: A review. J Am Soc Nephrol 1999;10:1366-1380.
22. Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: Azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol 1996;91:423-433.
23. Jain A, Venkataramanan R, Lever J, Warty V, Abu-Elmagd K, Furukawa H, et al. FK 506 in small bowel transplant recipients: Pharmacokinetics and dosing. Transplant Proc 1994;26:1609-1610.
24. Winkler M, Ringe B, Baumann J, Loss M, Wonigeit K, Pichlmayr R. Plasma vs. whole blood for therapeutic drug monitoring of patients receiving FK 506 for immunosuppression. Clin Chem 1994;40:2247-2253.
25. Laskow DA, Vincenti F, Neylan JF, Mendez R, Matas AJ. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. Transplantation 1996;62:900-905.
26. Kershner RP, Fitzsimmons WE. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation 1996;62:920-926.
27. Masuda S, Uemoto S, Hashida T, Inomata Y, Tanaka K, Inui K. Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient. Clin Pharmacol Ther 2000;68:98-103.
28. Masuda S, Uemoto S, Goto M, Fujimoto Y, Tanaka K, Inui K. Tacrolimus therapy according to mucosal MDR1 levels in smallbowel transplant recipients. Clin Pharmacol Ther 2004;75:352-361.